Drug Profile
JNJ 26483327
Alternative Names: JNJ-26483327; MTKi-327Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica
- Developer Janssen Pharmaceutica; Janssen Research & Development
- Class Antineoplastics; Macrocyclic compounds; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Src-Family kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (PO)
- 14 Oct 2011 JNJ 26483327 licensed to BeiGene worldwide
- 19 Nov 2009 Interim adverse events, pharmacokinetic and efficacy data from a phase I trial in Solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)